Results 171 to 180 of about 8,106 (209)

Incidence and risk factors for delayed intracranial hemorrhage after mild brain injury in anticoagulated patients: a multicenter retrospective study. [PDF]

Scand J Trauma Resusc Emerg Med
Capsoni N, Carpani G, Tarantino F, Gheda S, Cugnod JM, Lanfranchi S, Lee J, Lizza S, Marchesani S, Meloni E, Rigamonti A, Serrai I, Vergani S, Zuddio EG, Zumbo BG, Privitera D, Salinaro F, Bernasconi D, Secco G, Galbiati F, Perlini S, Bombelli M.   +21 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ticlopidine-Induced Lupus

JCR: Journal of Clinical Rheumatology, 2001
Ticlopidine is a widely used drug for prevention of stroke and other serious vascular events with a multitude of possible side effects. An increasing number of drugs are being recognized as the triggering agents of drug-induced lupus. We describe three patients in whom the etiologic connection between ticlopidine and lupus was supported by the ...
Alexandra Balbir-Gurman, Daniel Schapira, Ronit Sevilia, Yolanda Braun-Moscovici, Abraham Menahem Nahir   +4 more
openaire   +3 more sources

Delayed Neutropenia with Ticlopidine

Annals of Pharmacotherapy, 1994
OBJECTIVE: To report a case of ticlopidine-induced neutropenia occurring 18 days after discontinuation of the drug. CASE SUMMARY: A 68-year-old woman was placed on ticlopidine after a transient ischemic attack. Ten days later the drug was discontinued because the patient developed a rash.
Lori A. Hansen, Debra K Farver
openaire   +3 more sources

Ticlopidine-induced thrombocytopenia

The Netherlands Journal of Medicine, 1999
A case is presented of a 58-year-old woman developing profound thrombocytopenia within one week after starting treatment with ticlopidine. Ticlopidine was prescribed following coronary artery stenting. The patient recovered rapidly after discontinuation of the drug, suggesting a possible relationship between ticlopidine and thrombocytopenia ...
A. Loualidi, C.J. de Vries, J.J. Koornstra   +2 more
openaire   +3 more sources

Thienopyridine (Ticlopidin, Clopidogrel) [PDF]

Hämostaseologie, 1998
ZusammenfassungThienopyridine (Ticlopidin und Clopidogrel) hemmen spezifisch die ADP-medi- ierten Mechanismen der Thrombozytenaktivierung. Der genaue molekulare Wirkmechanismus der Thrombozytenfunktionshemmung durch Thienopyridine ist nicht bekannt.
A.-A. Weber, K. Schrör
openaire   +1 more source

Ticlopidine-theophylline interaction

Clinical Pharmacology and Therapeutics, 1987
Ticlopidine, a new antithrombotic agent, and theophylline, a widely used bronchodilator drug, are both almost completely metabolized in the liver. To evaluate an interaction between these two drugs, we studied theophylline pharmacokinetics before, after 10 days of ticlopidine administration, and 1 month later in 10 healthy volunteers. We found a highly
Roberto Parravicini, Gian Maria Elli, Guglielmo Buccino, Agostino Colli, Giancarlo Scaltrini, Massimo Cocciolo   +5 more
openaire   +3 more sources

The mechanisms of action of ticlopidine

Thrombosis Research, 1983
anti-platelet drug which was discovered in the laboratories of Parcor-Sanofi, Toulouse, France. This drug whose properties have been recently reviewed (1) has the potential as a clinically useful antithrombotic agent. It inhibits platelet aggregation induced by ADP and other aggregating agents (2).
openaire   +3 more sources

Ticlopidine and Antiplatelet Therapy

Annals of Pharmacotherapy, 1993
OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and toxicity of ticlopidine. Comparisons with other antiplatelet agents are presented, with an emphasis on efficacy, and a recommendation is provided regarding ticlopidine's place in therapy. DATA SOURCES: A MEDLINE literature retrieval of English-language journal articles from
Patricia Flores-Runk, Ralph H. Raasch
openaire   +3 more sources